Thyroid cancers are the most common malignancy of the endocrine system in humans. To understand the molecular genetic events underlying thyroid carcinogenesis, we have generated a mouse model that spontaneously develops follicular thyroid carcinoma similar to human thyroid cancer (ThrbPV/PV mouse). This mutant mouse harbors a dominant-negative mutated thyroid hormone receptor β (denoted PV). The PV mutation was identified in a patient with resistance to thyroid hormone (TH). ThrbPV/PV mice exhibit highly elevated serum thyroid-stimulating hormone levels and increased TH. We have previously shown that thyroid-stimulating hormone is required, but not sufficient to induce metastatic follicular thyroid cancer in ThrbPV/PV mice. However, whether the elevated TH also contributes to the thyroid carcinogenesis of ThrbPV/PV mice was not elucidated. To understand the role of TH in thyroid carcinogenesis, we blocked the production of TH by treating ThrbPV/PV mice with propylthiouracil (ThrbPV/PV-PTU mice) and compared the development of thyroid cancer in ThrbPV/PV-PTU and untreated ThrbPV/PV mice. We found that thyroid tumor growth was reduced by ∼42% in ThrbPV/PV-PTU mice as compared with ThrbPV/PV mice. Analysis by bromodeoxyuridine-nuclear labeling showed decreased incorporation of bromodeoxyuridine in thyroid tumor cells of ThrbPV/PV-PTU mice, indicative of decreased tumor cell proliferation. However, cleaved-caspase 3 staining showed no apparent changes in apoptosis of tumor cells in ThrbPV/PV-PTU mice. Molecular studies identified a marked attenuation of the PI3K–AKT–β-catenin signaling pathway that led to decreased protein levels of cyclin D2, thereby decreasing tumor cell proliferation in ThrbPV/PV-PTU mice. Furthermore, matrix metalloproteinase-2, a downstream target of β-catenin and a key regulator during tumor invasion and metastasis, was also decreased. Thus, the present study uncovers a critical role of TH in promoting the thyroid carcinogenesis of ThrbPV/PV mice via membrane signaling events. Importantly, these findings suggest that anti-thyroid drugs could be considered as possible therapeutic agents of thyroid cancer.
Thyroid carcinoma, the most common endocrine malignancy, is on the rise worldwide (Davies and Welch, 2006; Rego-Iraeta et al., 2009; Sassolas et al., 2009; Sipos and Mazzaferri, 2010). Thyroid cancers are mainly follicular cell-derived neoplasms, which include papillary thyroid carcinoma (∼80% of thyroid carcinomas), follicular thyroid carcinoma (FTC, <10%), poorly differentiated thyroid carcinoma (∼5%) and undifferentiated thyroid carcinoma/anaplastic thyroid carcinoma (<1%) (Nikiforov, 2004; Puxeddu et al., 2011). Several genomic abnormalities, including gene mutations (for example, rat sarcoma oncogene, RAS and v-raf murine sarcoma viral oncogene homolog B1, BRAF) and genomic rearrangements (for example, rearranged during transfection proto-oncogene/papillary thyroid carcinoma (RET-PTC) and paired box-8/peroxisome proliferator-activated receptor gamma (PAX8/PPARG) fusion gene), have been associated with thyroid cancers (Nikiforova and Nikiforov, 2009). However, how these genetic changes lead to thyroid cancers is not fully understood.
To understand the molecular mechanisms underlying thyroid carcinogenesis, we have created a mouse model (ThrbPV/PV mouse) that spontaneously develops FTC (Kaneshige et al., 2000; Suzuki et al., 2002). These mutant mice bear a knock-in mutated Thrb gene (ThrbPV) that encodes TRβPV, which has completely lost thyroid hormone (TH) binding and transcription activity (Kaneshige et al., 2000). The TRβPV mutant was identified in a patient with resistance to thyroid hormone (Parrilla et al., 1991). Extensive characterization of altered signaling pathways during thyroid carcinogenesis of the ThrbPV/PV mouse has identified activation of several tumor promoters such as β-catenin, cyclin D1, pituitary tumor transforming gene (PTTG), steroid receptor coactivator-3 (SRC-3) and phosphatidylinositol 3-kinase (PI3K), and the repression of tumor suppressors such as PPARγ (Ying et al., 2003, 2006, 2008; Furuya et al., 2006; Kim et al., 2007; Guigon et al., 2008). These altered signaling pathways during thyroid carcinogenesis of ThrbPV/PV mice are consistent with the changes reported in human thyroid cancers (Boelaert et al., 2003; Weinberger et al., 2007; Saji and Ringel, 2010). Thus, the ThrbPV/PV mouse is a valid mouse model to elucidate the molecular mechanisms underlying thyroid carcinogenesis.
Thyroid hormones (T3 and thyroxine, T4) have a critical role in development, growth and differentiation, and in maintaining metabolic homeostasis. They bind to thyroid hormone nuclear receptors (TRα and TRβ) to regulate target gene transcription (Cheng et al., 2010). In addition to mediating genomic actions, increasing lines of evidence also suggest that TH can initiate extranuclear functions through cytosolic thyroid hormone receptors (TRs) (Cheng et al., 2010) and/or via plasma membrane receptors (for example, integrin αvβ3) (Bergh et al., 2005; Davis et al., 2009). TH induces proliferation of several cancer cell lines, including breast, brain, pancreas and thyroid (Lin et al., 2007, 2009; Verga Falzacappa et al., 2007; Glinskii et al., 2009; Yalcin et al., 2010). The ThrbPV/PV mouse, similar to a homozygous patient with resistance to thyroid hormone (Ono et al., 1991), exhibits highly elevated thyroid-stimulating hormone (TSH) in the face of elevated TH (Kaneshige et al., 2000). Recently, using a mouse-genetics approach, we have clearly demonstrated that TSH signaling is essential, but not sufficient to induce the development of metastatic FTC (Lu et al., 2010). However, it is unclear whether elevated TH levels also affect the thyroid carcinogenesis of ThrbPV/PV mice. To explore the role of TH in thyroid carcinogenesis, we treated ThrbPV/PV mice with the goitrogen propylthiouracil (PTU) to block TH synthesis. We monitored the spontaneous development of thyroid cancer in these ThrbPV/PV-PTU mice and compared it with that in untreated ThrbPV/PV mice. Here we show that inhibition of TH synthesis by PTU treatment decreased thyroid tumor growth and delayed tumor progression in ThrbPV/PV mice. The decreased tumor cell proliferation was attributed to a marked attenuation of the PTEN-PI3K-AKT signaling pathway, resulting in reduction of cyclin D2 to decrease tumor cell proliferation. Reduction of β-catenin-matrix metalloproteinase-2 (MMP-2) signaling contributed to delayed tumor progression. Thus, the present study shows that TH, via membrane signaling pathways, acts to promote thyroid carcinogenesis in a mouse model of thyroid cancer.
Inhibition of thyroid hormone (TH) production by propylthiouracil (PTU) leads to the inhibition of follicular thyroid carcinoma (FTC) development in ThrbPV/PV mice
Our previous studies have shown that the development of FTC in ThrbPV/PV mice requires the TSH proliferation signal, whereas its progression, specifically metastasis, is attributed to the mutated TRβ (Lu et al., 2010, 2011). However, whether elevated TH levels also contribute to the thyroid carcinogenesis of ThrbPV/PV mice is unclear. To investigate the role of TH in FTC development in ThrbPV/PV mice, we treated ThrbPV/PV mice with PTU to block TH synthesis starting at 2 months and continuing on the PTU diet until the mice were killed for analyses. To confirm the effect of PTU, we measured serum levels of total T4 (TT4) and TSH in ThrbPV/PV and ThrbPV/PV-PTU mice (Figure 1). Consistent with the previous report (Kaneshige et al., 2000), an elevated serum level of TT4 was found in ThrbPV/PV mice (Figure 1a, TT4=19.52±1.44 μg/dl, n=10), and the TH level was greatly suppressed (Figure 1a, ThrbPV/PV-PTU mice, TT4=1.64±0.12 μg/dl, n=10), even lower than that of wild-type mice (WT; TT4=2.51±0.19 μg/dl, n=28, data not shown in the graph). However, PTU treatment did not affect serum TSH levels of ThrbPV/PV mice, as indicated in Figure 1b, in that no statistically significant differences were detected (8002±2263 ng/ml, n=10 and 12 790±3506 ng/ml, n=8 for ThrbPV/PV mice and ThrbPV/PV-PTU, respectively).
The first evidence suggesting that TH could have a role in FTC development was the decreased weight of thyroid tumors in ThrbPV/PV-PTU mice. As shown in Figure 2a, after PTU treatment for about 6–8 months, the thyroid weight was significantly reduced by ∼42% in ThrbPV/PV-PTU as compared with ThrbPV/PV mice. Pathohistological analyses of thyroid, heart and lung of moribund mice (age: 8–12 months) revealed a delayed tumor progression in ThrbPV/PV-PTU mice as compared with ThrbPV/PV mice. Figure 2b shows that in ThrbPV/PV mice, the frequencies of occurrence of capsular and vascular invasion were 100% and 83.3%, respectively. In ThrbPV/PV-PTU mice, by contrast, lower frequencies of occurrence of capsular invasion (87.5%) and vascular invasion (62.5%) were detected. Moreover, although 33% of ThrbPV/PV mice developed lung metastasis, only 25% of ThrbPV/PV-PTU mice did so. These data indicate that blocking TH synthesis delayed tumor progression in ThrbPV/PV mice.
Inhibition of thyroid hormone production by propylthiouracil treatment decreases proliferation of thyroid tumor cells in ThrbPV/PV mice with no apparent effect on apoptosis
Cell proliferation and apoptosis are two major processes that affect tumor growth. To determine which process was responsible for the decreased tumor growth due to the reduction of TH in ThrbPV/PV-PTU mice, we compared the extent of cell proliferation in the thyroids of both groups of mice by bromodeoxyuridine (BrdU) incorporation assay. To perform the assay, mice were intraperitoneally injected with BrdU 2 h before killing. Although no apparent positive signals were detected in the thyroid sections of WT mice (Figure 3A, panels a and b) under the experimental conditions, nuclei with BrdU incorporation were clearly visualized by immunostaining of thyroid sections of ThrbPV/PV mice (panels c and d) and ThrbPV/PV-PTU mice (panels e and f). However, fewer nuclei with incorporation of BrdU were observed in the treated mice. Sections from small intestine and brain tissue of WT mice were used as controls, representing cells with high and low proliferation rates, respectively (Figures 3A, g and h). To quantify the percentage of cells that were undergoing an active cell cycle within a 2-h BrdU-labeling period, we calculated the average ratio of BrdU-positive cells to total cells from 10–12 bright fields at high magnification ( × 400) of each section. The quantitative data are shown in Figure 3B. In WT mice, less than 1% of thyrocytes underwent DNA replication (Figures 3Aa, b and B), but more than 2.3% of cells from ThrbPV/PV mice were involved in the cell cycle (Figures 3Ac, d and B). After PTU treatment, this ratio dropped to 1.2% (52% reduction; Figures 3Ae, f and B), indicating a marked reduction in the proliferation of thyroid tumor cells when TH was decreased in ThrbPV/PV-PTU mice.
We also determined the effect of TH on apoptosis of thyroid tumor cells in these mice by assessing the abundance of cleaved caspase 3, a marker of apoptosis, by immunohistochemistry. No apparent changes of cleaved caspase 3 staining were found in ThrbPV/PV-PTU thyroid (Figure 3Cb) as compared with the control group (Figure 3Ca). We also measured the protein levels of B-cell lymphoma 2 (Bcl-2), a key regulator in apoptosis, by western blot analysis (Figure 3D). Similar protein levels of Bcl-2 were found in thyroid extracts of ThrbPV/PV and ThrbPV/PV-PTU mice. In addition, we further determined the protein levels of other apoptotic regulators, including B-cell lymphoma-extra large (Bcl-xL) and Bcl-2-interacting mediator of cell death (Bim). No apparent changes in protein levels of these apoptotic regulators were detected in ThrbPV/PV mice with or without PTU treatment (data not shown). Thus, consistent with cleaved caspase 3 staining, these results showed that a reduction of TH had no effect on apoptosis of thyroid tumor cells in ThrbPV/PV mice. On the basis of these findings, we concluded that reduced proliferation, but not apoptosis, contributed to the reduced thyroid tumor growth of ThrbPV/PV mice when TH was lowered.
Inhibition of thyroid hormone production by propylthiouracil treatment decreases activation of the integrin αvβ3-AKT signaling pathway in thyroids of ThrbPV/PV mice
It has been reported that TH increases proliferation of human thyroid cancer cell lines by activating the integrin αvβ3–MAPK signal transduction pathways (Lin et al., 2007). Similar TH effects via these pathways have also been reported in human glioma cell line (Lin et al., 2009). To dissect the molecular mechanisms of TH that led to the increased cell proliferation in FTC of ThrbPV/PV mice, we first examined the abundance of TH membrane receptor integrin αvβ3 at both transcriptional and translational levels. No differences in the mRNA levels were detected for either the Itgav or the Itgb3 gene between ThrbPV/PV and ThrbPV/PV-PTU mice (Supplementary Figures IA and B). However, western blot analysis showed that the protein level of integrin αv was lower in the thyroid tumor extract of ThrbPV/PV-PTU mice than in that of ThrbPV/PV mice (Figure 4Aa, compare lanes 3 and 4 to lanes 1 and 2). After normalization to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) loading controls (Figure 4Ac), a 60% decrease of integrin αv protein abundance was found in ThrbPV/PV-PTU mice. However, no apparent changes in protein levels of integrin subunit β3 were observed in ThrbPV/PV-PTU mice (Figure 4Ab, compare lanes 3 and 4 with lanes 1 and 2). These results suggest a downregulation of TH membrane receptor in response to decreased TH in thyroid tumor cells of ThrbPV/PV-PTU mice.
The PI3K-AKT signaling cascade is a critical pathway reported to be associated with the extranuclear signaling of TH-TRs (Cao et al., 2005; Verga Falzacappa et al., 2007). Direct association of TRβPV with the regulatory subunit p85α of PI3K activates PI3K-AKT signaling in tumor cells of ThrbPV/PV mice (Furuya et al., 2006). Accordingly, we addressed the question of whether TH affected the activated AKT by determining the protein abundance of phosphorylated AKT in thyroid tumors of ThrbPV/PV and ThrbPV/PV-PTU mice. Figure 4B shows that AKT phosphorylation was reduced (∼33%) in PTU-treated ThrbPV/PV mice (Figure 4Ba, compare lanes 4 and 5 with lanes 1–3). In contrast to the reduced phosphorylated AKT, no changes in the total amount of AKT protein were detected (Figure 4Bb). We also determined the phosphorylation status of glycogen synthase kinase 3β (GSK3β), a direct downstream target of AKT. It is known that GSK3β activity is inhibited by AKT phosphorylation, resulting in increased protein synthesis and proliferation in cells (Liang and Slingerland, 2003). Consistent with decreased activation of AKT (Figure 4Ba), western blot analysis revealed decreased phosphorylated GSK3β (Figure 4Bc, compare lanes 4 and 5 with lanes 1–3) in thyroid tumors of ThrbPV/PV-PTU mice without any change in total GSK3β protein levels (Figure 4Bd). Taken together, these results show that the lowering of TH leads to decreased AKT signaling.
Phosphatase and tensin homolog (PTEN) activity is increased in thyroid tumors of ThrbPV/PV-PTU mice
Phosphatase and tensin homolog (PTEN) has an essential role in opposing PI3K-AKT activation by negative regulation of the intracellular level of phosphatidylinositol-3,4,5-trisphosphate (PIP3). PTEN is also one of the tumor suppressors frequently lost in human cancers (Keniry and Parsons, 2008). We therefore assessed the expression of the Pten gene at both the translational and transcriptional levels. Western blot analysis revealed an elevated PTEN protein level (∼2.4-fold) in thyroid tumor extracts of ThrbPV/PV-PTU mice (Figure 5Aa, compare lanes 4 and 5 with lanes 1–3). Using real-time RT–PCR, we determined the Pten mRNA expression in tumors of ThrbPV/PV and ThrbPV/PV-PTU mice. Consistent with the increased protein levels of PTEN, a small (∼20%) but significantly elevated Pten mRNA was observed in ThrbPV/PV-PTU mice as compared with ThrbPV/PV mice (Figure 5B). These results indicate that decreased TH leads to activated expression of the Pten gene at both the mRNA and protein levels.
Downregulation of AKT activation suppresses the activity of β-catenin to inhibit thyroid growth in ThrbPV/PV mice
Aberrant activation of β-catenin by PI3K/AKT signaling pathways is a frequent event in thyroid cancers (Abbosh and Nephew, 2005; Castellone et al., 2009). Phosphorylation of β-catenin at Ser552 by AKT increases the translocation of β-catenin to nucleus, thereby activating its transcriptional activity to affect β-catenin downstream targets involved in cell proliferation (Fang et al., 2007). To understand whether β-catenin is the effector of activated AKT signaling in thyroid carcinogenesis, we compared the protein abundance of phosphorylated β-catenin at Ser552 in thyroid tumors between ThrbPV/PV and ThrbPV/PV-PTU mice. Figure 6A shows a reduction of phospho-Ser552-β-catenin (Figure 6Aa, compare lanes 4 and 5 with lanes 1–3) in ThrbPV/PV-PTU mice with no changes in total β-catenin (Figure 6Ab). One of the downstream targets of β-catenin critical for cell proliferation is cyclin D2 (Rowlands et al., 2004; Cole et al., 2010). To determine whether the reduced β-catenin affects the cyclin D2 protein level, we evaluated the protein abundance of cyclin D2 in thyroid tumors of ThrbPV/PV and ThrbPV/PV-PTU mice. Indeed, we found that the protein level of cyclin D2 was lower (by ∼38%) in ThrbPV/PV-PTU mice than in ThrbPV/PV mice (Figure 6Ba, compare lanes 3 and 4 with lanes 1 and 2). We also investigated the alteration of MMP2, a downstream target of β-catenin and a key regulator during tumor invasion and metastasis (Kessenbrock et al., 2010; Sonderegger et al., 2010), by western blot analysis. Consistent with the suppressed activity of β-catenin, a decrease in MMP2 protein level (∼51%) was also observed in ThrbPV/PV-PTU mice as compared with that in untreated mice (Figure 6Ca, compare lanes 3 and 4 with lanes 1 and 2). These results indicate that reduced β-catenin contributes to decreased tumor cell proliferation, and via MMP-2, delays the progression of invasion and metastasis in ThrbPV/PV-PTU mice.
Extensive phenotypic characterization and detailed molecular analyses have shown that thyroid tumor progression and altered signaling pathways in ThrbPV/PV mice mimic those observed in human thyroid cancers (Furuya et al., 2006; Ying et al., 2006, 2008; Guigon et al., 2008; Guigon and Cheng, 2009; Lu et al., 2010). Thus, the ThrbPV/PV mouse provides us with an unusual opportunity to investigate the role of TH in thyroid carcinogenesis. In ThrbPV/PV mice, the expression of a dominant-negative mutated TRβ (that is, PV) results in dysregulation of the pituitary–thyroid axis with elevated TSH in the face of elevated TH (Kaneshige et al., 2000). To understand how TH affects thyroid carcinogenesis, we treated ThrbPV/PV mice with PTU to block the synthesis of TH. As confirmed by hormone assays, ThrbPV/PV-PTU mice exhibited suppressed serum levels of TT4 as compared with the untreated ThrbPV/PV mice (Figure 1). However, PTU had no effect on the synthesis and secretion of TSH given that ThrbPV/PV-PTU mice maintained a TSH level as high as that of ThrbPV/PV mice. The similarly elevated serum levels of TSH would suggest that the thyroids of ThrbPV/PV and ThrbPV/PV-PTU mice received a similar stimulated activity from the TSH–TSH receptor pathway in promoting thyrocyte proliferation. The similarly elevated TSH level led us to conclude that the differences in phenotypes of thyroid tumors found between PTU-treated and untreated ThrbPV/PV mice were mainly conferred by the effects due to changes in TH levels. By decreasing TH levels in ThrbPV/PV mice, we observed reduced growth of thyroid tumors with delayed pathological progression. The reduced tumor size was mainly attributed to the decreased tumor cell proliferation with no changes in apoptotic status (Figures 2 and 3). Thus, TH acts to stimulate thyroid tumor cell proliferation of ThrbPV/PV mice.
To dissect the molecular mechanisms by which TH activated tumor cell proliferation, we focused on the studies of key regulators involved in membrane signaling events. Although TRβ is the major TR isoform in the thyroid, we reasoned that in ThrbPV/PV mice the mutant TRβ, PV, could no longer mediate TH actions. Moreover, we previously discovered that TRβPV acts not only in a dominant-negative fashion by nucleus-initiated events, but also by extranuclear signaling by activating the PI3K-AKT pathway (Furuya et al., 2006, 2007), as well as by increasing the stability of β-catenin (Guigon et al., 2008, 2010), thereby promoting thyroid carcinogenesis in ThrbPV/PV mice (Lu and Cheng, 2011). Accordingly, we ascertained which players in the TRβPV-mediated extranuclear PI3K-AKT pathway were affected by TH. Indeed, we found that the upstream negative regulator of PI3K-AKT signaling, PTEN, was markedly increased when TH was reduced in ThrbPV/PV-PTU mice (Figure 5, also see Figure 7), leading to an attenuation of PI3K-AKT signaling (Figures 4 and 7). Consistently, the protein abundance of phosphorylated β-catenin, a critical downstream key effector of PI3K-AKT signaling, was reduced when TH was lowered, leading to reduced cyclin D2 to decrease cell proliferation. Thus, the present study has uncovered an effect of TH that modulates the activity of the PTEN–PI3K–AKT–β-catenin–cyclin D2 pathway to affect the tumor cell proliferation and carcinogenesis of the thyroid of ThrbPV/PV mice.
At present, how TH regulates the expression of the Pten gene is not clear. In addition to an increased protein abundance of PTEN (Figure 5A) when TH was lowered, we found a small but significant increase in the mRNA expression of the Pten gene in ThrbPV/PV-PTU mice (Figure 5B). One possibility that could be considered to account for the increased expression of the Pten gene protein is by the TH membrane receptor, integrin αvβ3, reported by Davis and his group (Bergh et al., 2005; Lin et al., 2009; Cheng et al., 2010). Actions of TH on the integrin αvβ3 receptor have been demonstrated in many cell types with diverse cellular effects, such as T4-simulated angiogenesis on vessel endothelial cells and enhanced proliferation of tumor cells, including breast cancer, glioblastoma and thyroid cancer cell lines (Davis et al., 2004; Mousa et al., 2006; Glinskii et al., 2009; Lin et al., 2009). The present study showed decreased protein abundance of integrin subunit αv, albeit with no changes of β3 protein levels when TH was lowered in ThrbPV/PV-PTU mice (Figure 4A). It is possible that the expression of the Pten gene is affected by dampening integrin αvβ3 signaling, followed by relaying the signals via MAPK phosphorylation cascades (Bergh et al., 2005; Lin et al., 2007) to reach the ultimate downstream nuclear events (yet to be identified). However, this possibility awaits future studies to be tested and validated.
The data from the present molecular study led us to propose a model (see Figure 7) that supports the contention that one mechanism by which TH acted was by integrin-mediated extranuclear signaling. TRβ is the major TR isoform in the thyroid, and is mutated to PV that cannot bind TH in ThrbPV/PV mice. However, at present, we could not exclude the possibility that TH could potentially mediate its proliferative effects by TRα1-initiated nuclear genomic signaling events. However, PV is known to be a potent dominant-negative mutant (Parrilla et al., 1991; Kaneshige et al., 2000). The possibility exists that it could also act to interfere with the transcription activity of TRα1. However, at present, no data are available to clarify the role of TRα1 in mediating TH effects in the thyroid of ThrbPV/PV mice.
Association studies have shown that amplification of the PIK3CA gene and aberrant activation of AKT are frequent in human thyroid cancer (Hou et al., 2007; Saji and Ringel, 2010; Xing, 2010), demonstrating the crucial role of PI3K-AKT signaling in thyroid carcinogenesis. Recently, using a mouse model of FTC in which two alleles of the Pten gene were selectively deleted in the thyroid, Antico-Arciuch et al. (2010) showed a direct role of estrogens in increasing thyrocyte proliferative index by crosstalk with the PI3K pathway. The present study identified TH as a critical hormonal stimulator to promote thyroid carcinogenesis of ThrbPV/PV mice by regulating the PI3K-AKT signaling. The present data have shown that TH acts to promote tumor cell proliferation by PI3K–AKT–β-catenin–cyclin D2 signaling. In view of these findings, anti-thyroid drugs could be considered as potential therapeutic agents for the treatment of thyroid cancer.
Materials and methods
All aspects of animal care and experimentation were approved by the National Cancer Institute Animal Care and Use Committee. ThrbPV/PV mice used in the present study were the offspring of many generations of intersibling mating over 6 years (more than 30 generations). For the PTU treatment group, ThrbPV/PV mice were fed an iodine-deficient diet supplemented with 0.15% PTU (cat. no.; TD.95125, Harlan Laboratories, Inc., Indianapolis, IN, USA) beginning at the age of 2 months and continuing on the PTU diet until the mice were killed for analyses. Control group mice were fed a normal mouse diet. Moribund mutant mice and PTU-treated littermates were euthanized to harvest tissues for weighing, histological analysis and biochemical studies.
Determination of serum levels of total T4 and thyroid-stimulating hormone by radioimmunoassay
Blood was collected from the mice before killing. The serum level of TT4 was determined by using a Gamma Coat T4 assay radioimmunoassay kit (Dia-Sorin, Stillwater, MN, USA) according to the manufacturer's instructions. TSH levels in serum were measured as previously described (Kaneshige et al., 2000).
Histology and immunohistochemistry
For histological evaluation, thyroid glands were fixed in 10% neutral-buffered formalin and subsequently embedded in paraffin. Five-μm-thick sections were prepared and stained with hematoxylin and eosin for histopathological analysis. Immunohistochemistry was also performed with paraffin sections by standard methods. In brief, de-waxed sections were processed using 0.05% citraconic anhydride buffer (pH 7.4) at 98 °C for 45 min to expose the antigen epitopes. The primary antibody, rabbit anti-cleaved caspase 3 antibody (1:50 dilution, Cell Signaling Technology, Danvers, MA, USA), was incubated with tissues overnight at 4 °C. Peroxidase activity from the secondary antibody was detected by adding substrate 3,3′-diaminobenzidine, and the sections were counterstained with hematoxylin.
Bromodeoxyuridine incorporation assay
To measure the thyrocyte proliferation rate, the BrdU incorporation assay was performed. In brief, mice were injected intraperitoneally with BrdU at 50 μg/g of body weight and then killed 2 h after the injection. Tissues were processed and immunohistochemistry was performed on paraffin sections as described above with some modifications. Briefly, de-waxed slides were treated with Antigen Unmasking solution (Vector Laboratories, Burlingame, CA, USA) in the microwave for 20 min after boiling, and stained with mouse anti-BrdU antibody (1:10 dilution, Cat. no.; 347589, Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) overnight at 4 °C. The quantification of BrdU-positive cells was performed on digital images captured under × 400 magnification of each thyroid section. Two randomly selected slides from three thyroids of each group were analyzed. For each slide, ratios of BrdU-positive cells/total cells from 10–12 bright fields under × 400 amplification were calculated.
Western blot analysis
Protein extracts from thyroids dissected from ThrbPV/PV and ThrbPV/PV-PTU mice were prepared as described previously (Lu et al., 2010). About 30–40 μg of protein extract was analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and the western blot analysis was carried out (Furumoto et al., 2005). Primary antibodies for phosphorylated-Ser473-AKT, total AKT, p-Ser21/9-GSK-3α/β, total GSK-3β, p-Ser552-β-catenin, p-Ser33/37/Thr41-β-catenin, total β-catenin, cleaved caspase 3, cyclin D2 and GAPDH were purchased from Cell Signaling Technology. Antibodies for integrin αv, integrin β3 and MMP-2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Quantitative real-time RT–PCR
Total RNA from five to seven mouse thyroids in each experimental group was extracted by TRIzol (Invitrogen, Carlsbad, CA, USA), followed by RNase-free DNase treatment (Qiagen, Valencia, CA, USA) and column purification (RNeasy Mini Kit, Qiagen). For real-time reverse transcription–PCR (RT–PCR), one-step RT–PCR reactions were performed with 50 ng of total RNA using a QuantiTect SYBR Green RT–PCR kit (Qiagen) in a Roche LightCycler PCR instrument (Roche, Indianapolis, IN, USA) with specific primers as follows: mItgav-F2773: 5′-IndexTermCTGCACGGCAGATACAGAGATC-3′; mItgav-R2935: 5′-IndexTermGCACTTGGCGATTCCACAGC-3′; mItgb3-F582: 5′-IndexTermCAAGCCTGTATCGCCGTACATG-3′; mItgb3-R760: 5′-IndexTermCATCTCGATTACGGGACACGCTC-3′; mPten-F1-1427: 5′-IndexTermGATTACAGACCCGTGGCACT-3′; mPten-R1-1606: 5′-IndexTermTGGCTGAGGGAACTCAAAGT-3′; mGapdh-F2-436: 5′-IndexTermTTGTGATGGGTGTGAACCAC-3′; m-Gapdh-R2-674: 5′-IndexTermGGATGCAGGGATGATGTTCT-3′. The reaction conditions were 50 °C for 20 min; 95 °C for 15 min; 40–45 cycles of 95 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s; and 65–95 °C with a heating rate of 0.1 °C/s and a cooling step to 40 °C.
All data of radioimmunoassays were expressed as mean±s.e.m. The statistical analyses on these data were performed using a one-way analysis of variance followed by Bonferroni's post hoc test for multiple comparisons (Prism, GraphPad, San Diego, CA, USA). P<0.05 was considered as statistically significant. For western blot results, films were scanned and the intensity of each band was quantified by ImageJ Analysis Software (NIH, Bethesda, MD, USA). Data were normalized against GAPDH or calculated as a ratio between phosphorylated and total protein levels. For real-time RT–PCR, the Gapdh gene expression was used as an internal control. The statistical analysis was performed using an unpaired t-test by Prism software (GraphPad). P<0.05 was considered as statistically significant.
Abbosh PH, Nephew KP . (2005). Multiple signaling pathways converge on beta-catenin in thyroid cancer. Thyroid 15: 551–561.
Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A . (2010). Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene 29: 5678–5686.
Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S et al. (2005). Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146: 2864–2871.
Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC et al. (2003). Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 88: 2341–2347.
Cao X, Kambe F, Moeller LC, Refetoff S, Seo H . (2005). Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol Endocrinol 19: 102–112.
Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F et al. (2009). The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 69: 1867–1876.
Cheng SY, Leonard JL, Davis PJ . (2010). Molecular aspects of thyroid hormone actions. Endocr Rev 31: 139–170.
Cole AM, Myant K, Reed KR, Ridgway RA, Athineos D, Van den Brink GR et al. (2010). Cyclin D2-cyclin-dependent kinase 4/6 is required for efficient proliferation and tumorigenesis following Apc loss. Cancer Res 70: 8149–8158.
Davies L, Welch HG . (2006). Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295: 2164–2167.
Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ et al. (2004). Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94: 1500–1506.
Davis PJ, Davis FB, Lin H-Y, Mousa SA, Zhou M, Luidens MK . (2009). Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metabol 297: E1238–E1246.
Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H et al. (2007). Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282: 11221–11229.
Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS et al. (2005). An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25: 124–135.
Furuya F, Hanover JA, Cheng SY . (2006). Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci USA 103: 1780–1785.
Furuya F, Lu C, Willingham MC, Cheng SY . (2007). Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 28: 2451–2458.
Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB et al. (2009). Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8: 3554–3562.
Guigon CJ, Cheng SY . (2009). Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol Cell Endocrinol 308: 63–69.
Guigon CJ, Kim DW, Zhu X, Zhao L, Cheng SY . (2010). Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression. Endocrinology 151: 5528–5536.
Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY . (2008). Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 28: 4598–4608.
Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S et al. (2007). Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13: 1161–1170.
Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA et al. (2000). Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97: 13209–13214.
Keniry M, Parsons R . (2008). The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477–5485.
Kessenbrock K, Plaks V, Werb Z . (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52–67.
Kim CS, Ying H, Willingham MC, Cheng SY . (2007). The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer. Carcinogenesis 28: 932–939.
Liang J, Slingerland JM . (2003). Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339–345.
Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA et al. (2009). L-Thyroxine vs 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296: C980–C991.
Lin HY, Tang HY, Shih A, Keating T, Cao G, Davis PJ et al. (2007). Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 72: 180–187.
Lu C, Cheng SY . (2011). Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. Steroids 76: 885–891.
Lu C, Mishra A, Zhu YJ, Meltzer P, Cheng SY . (2011). Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma. Am J Cancer Res 1: 1–13.
Lu C, Zhao L, Ying H, Willingham MC, Cheng SY . (2010). Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology 151: 1929–1939.
Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X . (2006). Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25: 407–413.
Nikiforov YE . (2004). Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15: 319–327.
Nikiforova MN, Nikiforov YE . (2009). Molecular diagnostics and predictors in thyroid cancer. Thyroid 19: 1351–1361.
Ono S, Schwartz ID, Mueller OT, Root AW, Usala SJ, Bercu BB . (1991). Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J Clin Endocrinol Metab 73: 990–994.
Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD . (1991). Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two ‘hot spot’ regions of the ligand binding domain. J Clin Invest 88: 2123–2130.
Puxeddu E, Romagnoli S, Dottorini ME . (2011). Targeted therapies for advanced thyroid cancer. Curr Opin Oncol 23: 13–21.
Rego-Iraeta A, Perez-Mendez LF, Mantinan B, Garcia-Mayor RV . (2009). Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid 19: 333–340.
Rowlands TM, Pechenkina IV, Hatsell S, Cowin P . (2004). Beta-catenin and cyclin D1: connecting development to breast cancer. Cell Cycle 3: 145–148.
Saji M, Ringel MD . (2010). The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321: 20–28.
Sassolas G, Hafdi-Nejjari Z, Remontet L, Bossard N, Belot A, Berger-Dutrieux N et al. (2009). Thyroid cancer: is the incidence rise abating? Eur J Endocrinol 160: 71–79.
Sipos JA, Mazzaferri EL . (2010). Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22: 395–404.
Sonderegger S, Haslinger P, Sabri A, Leisser C, Otten JV, Fiala C et al. (2010). Wingless (Wnt)-3A induces trophoblast migration and matrix metalloproteinase-2 secretion through canonical Wnt signaling and protein kinase B/AKT activation. Endocrinology 151: 211–220.
Suzuki H, Willingham MC, Cheng SY . (2002). Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12: 963–969.
Verga Falzacappa C, Petrucci E, Patriarca V, Michienzi S, Stigliano A, Brunetti E et al. (2007). Thyroid hormone receptor TRbeta1 mediates Akt activation by T3 in pancreatic beta cells. J Mol Endocrinol 38: 221–233.
Weinberger PM, Adam BL, Gourin CG, Moretz 3rd WH, Bollag RJ, Wang BY et al. (2007). Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg 133: 503–510.
Xing M . (2010). Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20: 697–706.
Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, Mousa SS et al. (2010). Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20: 281–286.
Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA et al. (2006). Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest 116: 2972–2984.
Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY . (2003). Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res 63: 5274–5280.
Ying H, Willingham MC, Cheng SY . (2008). The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer. Oncogene 27: 823–830.
This research was supported by the Intramural Research Program of National Institutes of Health, National Cancer Institute, Center for Cancer Research.
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on the Oncogene website
About this article
Cite this article
Lu, C., Zhu, X., Willingham, M. et al. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma. Oncogene 31, 2007–2016 (2012). https://doi.org/10.1038/onc.2011.390
- thyroid hormone
- follicular thyroid carcinoma
- animal model
- protein kinase B/AKT